# Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

> **NCT07218913** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 44 (estimated)

## Conditions studied

- Hearing Loss
- Metastatic Malignant Germ Cell Tumor
- Metastatic Malignant Nongerminomatous Germ Cell Tumor
- Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor
- Metastatic Testicular Seminoma
- Stage II Testicular Cancer AJCC v8
- Stage III Testicular Cancer AJCC v8

## Interventions

- **PROCEDURE:** Audiometric Test
- **DRUG:** Cisplatin
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Sodium Thiosulfate Anhydrous

## Key facts

- **NCT ID:** NCT07218913
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-19
- **Primary completion:** 2031-01-22
- **Final completion:** 2031-01-22
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07218913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07218913, "Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07218913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*